First Tracks Biotherapeutics, Inc. (TRAX) stock
TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026
$44.50+0.93 (+2.13%)
Close on Nov 18, 2026Market cap $1.59BP/E –Yield –
First Tracks Biotherapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$17.05M | – |
| Q2 FY2026 | Jun 30, 2026 | -$31.94M | – |
| Q1 FY2026 | Mar 31, 2026 | -$32.58M | – |
| Q3 FY2025 | Sep 30, 2025 | -$30.70M | – |
| Q2 FY2025 | Jun 30, 2025 | -$38.68M | – |
| Q1 FY2025 | Mar 31, 2025 | -$45.04M | – |
See a number that looks wrong?